Effects of renal sympathetic denervation on the course of congestive heart failure combined with chronic kidney disease: Insight from studies with fawn-hooded hypertensive rats with volume overload induced using aorto-caval fistula

References

• Bullock H, Yellon DM, Hausenloy DJ.Reducing myocardial infarct size: challenges and future opportunities. Heart. 2016;102(5):341–48. doi:10.1136/heartjnl-2015-307855.
   PubMed Web of Science ®Google Scholar
• Mathers CD, Loncar D.Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. doi:10.1093/eurheartj/ehw128. Authors/Task Force Members.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation. 2017;135:e146–e603.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Xanthopoulos A, Butler J.Cardiovascular aging and heart failure: JAAC review topic of the week. J Am Coll Cardiol. 2019;74(6):804–13. doi:10.1016/j.jacc.2019.06.053.
   PubMed Web of Science ®Google Scholar
• McCullough KP, Morgenstern H, Saran R, Herman WH, Robinson BN.Projecting ESRD incidence and prevalence in the United States through 2030. J Am Soc Nephrol. 2019;30(1):127–35. doi:10.1681/ASN.2018050531.
   PubMed Web of Science ®Google Scholar
• Saran R, Robinsion B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrsihnan R.US renal data system 2018 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2019;73(3S1):A7–A8. doi:10.1053/j.ajkd.2019.01.001.
   PubMedGoogle Scholar
• Di Nicoló P.The dark side of the kidney in cardio-renal syndrome: renal venous hypertension and congestive kidney failure. Heart Fail Rev. 2018;23(2):291–302. doi:10.1007/s10741-018-9673-4.
   PubMed Web of Science ®Google Scholar
• House AA.Management of heart failure in advancing CKD: core curriculum 2018. Am J Kidney Dis. 2018;72(2):284–95. doi:10.1053/j.ajkd.2017.12.006.
   PubMed Web of Science ®Google Scholar
• Mullens W, Verbrugge FH, Nijst P, Tang WHW.Renal sodium avidity in heart failure: from pathophysiology to treatment strategies. Eur Heart J. 2017;38(24):1872–82. doi:10.1093/eurheartj/ehx035.
   PubMed Web of Science ®Google Scholar
• Hein AM, Scialla JJ, Edmonston D, Cooper LB, DeVore AD, Mentz RJ.Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. JACC Heart Fail. 2019;7(5):371–82. doi:10.1016/j.jchf.2019.02.009.
   PubMed Web of Science ®Google Scholar
• Rangawwami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezeu K, Molitch M, Mullens W, et al., American Heart Asssociation Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies. A scientific statement from the American heart association. Circulation. 2019;139(16):e840–e878. doi:10.1161/CIR.0000000000000664.
   PubMed Web of Science ®Google Scholar
• Kassi M, Hannawi B, Trachtenberg B.Recent advances in heart failure. Curr Opin Cardiol. 2018;33(2):249–56. doi:10.1097/HCO.0000000000000497.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Hernandez AF, Solomon SD, Zannad F.Heart failure drug treatment. Lancet. 2019;393(10175):1034–44. doi:10.1016/S0140-6736(18)31808-7.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, Skoulargis J, Louridas G, Butler J.The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747–62. doi:10.1016/j.jacc.2009.05.015.
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Sobotka PA, Bart BA.The sympathorenal axis in hypertension and heart failure. J Cardiac Fail. 2010;16(5):369–73. doi:10.1016/j.cardfail.2009.12.022.
   PubMed Web of Science ®Google Scholar
• Florea VG, Cohn JN.The autonomic nervous system and heart failure. Circ Res. 2014;114(11):1815–26. doi:10.1161/CIRCRESAHA.114.302589.
   PubMed Web of Science ®Google Scholar
• Antoine S, Vaidya G, Imam H, Villarreal D.Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. Am J Med Sci. 2017;353(1):27–30. doi:10.1016/j.amjms.2016.06.016.
   PubMed Web of Science ®Google Scholar
• Singh RB, Hristova K, Fedacko J, El-Kilany G, Cornelissen G.Chronic heart failure: a disease of the brain. Heart Fail Rev. 2019;24(2):301–07. doi:10.1007/s10741-018-9747-3.
   PubMed Web of Science ®Google Scholar
• Blankestijn PJ.Sympathetic hyperactivity in chronic kidney disease. Nephrol Dial Transplant. 2004;19(6):1354–57. doi:10.1093/ndt/gfh242.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, et al.Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105(11):1354–59. doi:10.1161/hc1102.105261.
   PubMed Web of Science ®Google Scholar
• Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, Dell´Oro R, Mancia G.Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57(4):846–51. doi:10.1161/HYPERTENSIONAHA.110.164780.
   PubMed Web of Science ®Google Scholar
• Kaur J, Young BE, Fadel PJ. Sympathetic overactivity in chronic kidney disease: consequences and mechanism. Int J Mol Sci. 2017;18:E1682. doi:10.3390/ijms18081682.
   PubMed Web of Science ®Google Scholar
• Weber MA, Mahfoud F, Schmieder RE, Kandzari DE, Tsioufis KP, Twonsend RR, Kario K, Bohm M, Sharp ASP, Davies JE, et al.Renal denervation for treating hypertension. JACC Cardiovasc Interv. 2019;12(12):1095–105. doi:10.1016/j.jcin.2019.02.050.
   PubMed Web of Science ®Google Scholar
• Polhemus DJ, Trivedi RK, Gao J, Li Z, Scarborough AL, Goodchild TT, Varner KJ, Xia H, Smart FW, Kapusta DR, et al.Renal sympathetic denervation protects the failing heart via inhibition of neprilysin activity in the kidney. J Am Coll Cardiol. 2017;70(17):2139–53. doi:10.1016/j.jacc.2017.08.056.
   PubMed Web of Science ®Google Scholar
• Sharp TE III, Polhemus DJ, Liz Z, Spaletra P, Jenkins JS, Reilly JP, White CJ, Kapusta DR, Lefer DJ, Goodchild TT.Renal denervation prevents heart failure progression via inhibition of the renin-angiotensin system. J Am Coll Cardiol. 2018;72(21):2609–21. doi:10.1016/j.jacc.2018.08.2186.
   PubMed Web of Science ®Google Scholar
• Sharp TE III, Lefer DJ.Renal denervation to treat heart failure. Annu Rev Physiol. 2021;83(1):4.1–4.20. doi:10.1146/annurev-physiol-031620-093431.
   PubMedGoogle Scholar
• Hering D, Marusic P, Duval J, Sata Y, Head GA, Denton KM, Burrows S, Walton AS, Esler MD, Schlaich MP. Effect of renal denervation on kidney function in patients with chronic kidney disease. Int J Cardiol. 2017;232:93–97. doi:10.1016/j.ijcard.2017.01.047.
   PubMed Web of Science ®Google Scholar
• Kiuchi MG, Graciano M, Carreira MA, Kiuchi T, Cehn S, Lugon JR.Long-term effects of renal sympathetic denervation on hypertensive patients with mild to moderate chronic kidney disease. J Clin Hypertens. 2016;18(3):190–96. doi:10.1111/jch.12724.
   Web of Science ®Google Scholar
• Sanders MF, Blankestijn PJ. Chronic kidney disease as a potential indication for renal denervation. Front Physiol. 2016;7:220. doi:10.3389/fphys.2016.00220.
   PubMed Web of Science ®Google Scholar
• Mahfoud F, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Rouilope L, Schlaich M, Williams B, Fahy M, Mancia G.Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from global SYMPLICITY registry. Eur Heart J. 2019;40(42):3474–82. doi:10.1093/eurheartj/ehz118.
   PubMed Web of Science ®Google Scholar
• Eriguchi M, Tsuruya K, Haruyama N, Yamada S, Tanaka S, Suehiro T, Noguchi H, Masutani K, Torisu K, Kitazono T.Renal denervation has blood pressure-independent protective effects on kidney and heart in a rat model of chronic kidney disease. Kidney Int. 2015;87(1):116–27. doi:10.1038/ki.2014.220.
   PubMed Web of Science ®Google Scholar
• Abassi Z, Goltsmna I, Karram T, Winaver J, Horrman A. Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy. J Biomed Biotechnol. 2011;2011:729497. doi:10.1155/2011/729497.
   PubMedGoogle Scholar
• Brower GL, Levick SP, Janicki JS.Differential effects of prevention and reversal treatment with Lisinopril on left ventricular remodeling in a rat model of heart failure. Heart Lung Circ. 2015;24(9):919–24. doi:10.1016/j.hlc.2015.02.023.
   PubMed Web of Science ®Google Scholar
• Cohen-Segev R, Francis B, Abu-Saleh N, Awad H, Lazarovich A, Kabala A, Aronson D, Abassi Z.Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure. Acta Histiochem. 2014;116(8):1342–49. doi:10.1016/j.acthis.2014.08.006.
   PubMed Web of Science ®Google Scholar
• Červenka L, Melenovský V, Husková Z, Škaroupková P, Nishiyama A, Sadowski J.Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula. Clin Exp Pharmacol Physiol. 2015;42(7):795–807. doi:10.1111/1440-1681.12419.
   PubMed Web of Science ®Google Scholar
• Kala P, Sedláková L, Škaroupková P, Kopkan L, Vaňourková Z, Táborský M, Nishiyama A, Hwang SH, Hammock BD, Sadowski J, et al. Effects of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula. Physiol Res. 2018;67:401–15.
   PubMed Web of Science ®Google Scholar
• Kratky V, Kopkan L, Kikerlova S, Huskova Z, Taborsky M, Sadowski J, Kolar F, Cervenka L.The role of renal vascular reactivity in the development of renal dysfunction in compensated and decompensated congestive heart failure. Kidney Blood Press Res. 2018;43(6):1730–41. doi:10.1159/000495391.
   PubMed Web of Science ®Google Scholar
• Vacková Š, Kikerlová S, Melenovský V, Kolář F, Imig JD, Kompanowska-Jezierska E, Sadowski J, Červenka L.Altered renal vascular responsiveness to vasoactive agents in rats with angiotensin II-dependent hypertension and congestive heart failure. Kidney Blood Press Res. 2019;44(4):792–809. doi:10.1159/000501688.
   PubMed Web of Science ®Google Scholar
• Houser SR, Margulies KB, Murphy AM, Spinale FG, Francis GS, Prabhu SD, Rockman HA, Kass DA, Molkentin JD, Sussman MA, et al.Animal models of heart failure: a scientific statement from the American heart association. Circ Res. 2012;111(1):131–50. doi:10.1161/RES.0b013e3182582523.
   PubMed Web of Science ®Google Scholar
• Kuijpers MH, De Jong W.Spontaneous hypertension in the fawn-hooded rat: a cardiovascular disease model. J Hypertens Suppl. 1986;4(3):S41–S44.
   PubMedGoogle Scholar
• Kuijpers MH, Provoost AP, De Jong W.Development of hypertension and proteinuria with age in fawn-hooded rats. Clin Exp Pharmacol Physiol. 1986;13(3):201–09. doi:10.1111/j.1440-1681.1986.tb00338.x.
   PubMed Web of Science ®Google Scholar
• Doleželová Š, Jíchová Š, Husková Z, Vojtíšková A, Kujal P, Hošková L, Kautzner J, Sadowski J, Červenka L, Kopkan L.Progression of hypertension and kidney disease in aging fawn-hooded rats is mediated by enhanced influence of renin-angiotensin system and suppression of nitric oxide system and epoxyeicosanoids. Clin Exp Hypertens. 2016;38(7):644–51. doi:10.1080/10641963.2016.1182182.
   PubMed Web of Science ®Google Scholar
• Vacková Š, Kopkan L, Kikerlová S, Husková Z, Sadowski J, Kompanowska-Jezierska E, Hammock BD, Imig JD, Táborský M, Melenovský V, et al. Pharmacological blockade of soluble epoxide hydrolase attenuates the progression of congestive heart failure combined with chronic kidney disease: insights from studies with fawn-hooded hypertensive rats. Front Pharmacol. 2019;10:18. doi:10.3389/fphar.2019.00018.
   PubMed Web of Science ®Google Scholar
• Osborn JW, Foss JD. Renal nerves and long-term control of arterial pressure. Compr Physiol. 2017;7:263–320.
   PubMed Web of Science ®Google Scholar
• Pinkham MI, Loftus MT, Amirapu S, Guild SJ, Quill G, Woodward WR, Habecker BA, Barrett CJ. Renal denervation in male rats with heart failure improves ventricular sympathetic nerve innervation and function. Am J Physiol. 2017;312:R368–R379.
   Google Scholar
• Bello-Reuss E, Colindres RE, Pastoriza-Monuz E, Mueller RA, Gottschalk CW.Effect of acute unilateral renal denervation in the rat. J Clin Invest. 1975;56(1):208–17. doi:10.1172/JCI108069.
   PubMed Web of Science ®Google Scholar
• Ichihara A, Inscho EW, Imig JD, Michel RE, Navar LG.Role of renal nerves in afferent arteriolar reactivity in angiotensin-induced hypertension. Hypertension. 1997;29(1):442–49. doi:10.1161/01.HYP.29.1.442.
   PubMed Web of Science ®Google Scholar
• Kline RL, Mercer PF.Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. Am J Physiol. 1980;238(5):R353–R358. doi:10.1152/ajpregu.1980.238.5.R353.
   PubMedGoogle Scholar
• Husková Z, Kramer HJ, Vaňourková Z, Červenka L.Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens. 2006;24(3):517–27. doi:10.1097/01.hjh.0000209988.51606.c7.
   PubMed Web of Science ®Google Scholar
• Fox J, Guan S, Hymel AA, Navar LG, Dietary N.ACE inhibition effects on renal tissue angiotensin I and II and ACE activity in rats. Am J Physiol. 1992;262(5 Pt 2):F902–F909. doi:10.1152/ajprenal.1992.262.5.F902.
   PubMedGoogle Scholar
• Husková Z, Kopkan L, Červenková L, Doleželová Š, Vaňourková Z, Škaroupková P, et al. Intrarenal alterations of the angiotensin-converting type 2/angiotensin 1-7 complex of the renin-angiotensin system do not alter the course of malignant hypertension in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol. 2016;43(4):438–49. doi:10.1111/1440-1681.12553.
   PubMed Web of Science ®Google Scholar
• Čertíková Chábová V, Kujal P, Škaroupková P, Vaňourková Z, Vacková Š, Husková Z, Kikerlová S, Sadowski J, Kompanowska-Jezierska E, Baranowska I, et al.Combined inhibition of soluble epoxide hydrolase and renin-angiotensin system exhibits superior renoprotection to renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic hypertensive rats with established chronic kidney disease. Kidney Blood Press Res. 2018;43(2):329–49. doi:10.1159/000487902.
   PubMed Web of Science ®Google Scholar
• Čertíková Chábová V, Kujal P, Škaroupková P, Sadowski J, Kompanowska-Jezierska E, Tesař V, Hammock B, Imig JD, Maxová H, Červenka L, et al.Addition of endothelin A-receptor blockade spoils the beneficial effect of combined renin-angiotensin and soluble epoxide hydrolase inhibition: studies on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Kidney Blood Press Res. 2019;44(6):1493–505. doi:10.1159/000504137.
   PubMed Web of Science ®Google Scholar
• Lohmeier TE, Hall JE.Device-based neuromodulation for resistant hypertension therapy. Too early for prime time? Circ Res. 2019;124(7):1071–93. doi:10.1161/CIRCRESAHA.118.313221.
   PubMed Web of Science ®Google Scholar
• Honetschlagerová Z, Škaroupková P, Kikerlová S, Vaňourková Z, Husková Z, Melenovský V, Kompanowska-Jezierska E, Sadowski J, Červenka L. Renal sympathetic denervation attenuates congestive heart failure in angiotensin II-dependent hypertension: studies with Ren-2 transgenic hypertensive rats with aorto-caval fistula. Kidney Blood Press Res. 2021;1–19. doi:10.1159/000513071.
   Web of Science ®Google Scholar
• Krátký V, Kikerlová S, Husková Z, Sadowski J, Kolář F, Červenka L.Enhanced renal vascular responsiveness to angiotensin II and norepinephrine: a unique feature of female rats with congestive heart failure. Kidney Blood Press Res. 2019;44(5):1128–41. doi:10.1159/000502379.
   PubMed Web of Science ®Google Scholar
• Kala P, Bartušková H, Piťha J, Vaňourková Z, Kikerlová S, Jíchová Š, Melenovský V, Hošková L, Veselka J, Kompanowska-Jezierska E, et al. 2020. Deleterious effects of hyperactivity of the renin-angiotensin system and hypertension on the course of chemotherapy-induced heart failure after doxorubicin administration: a study in Ren-2 transgenic rats. Int J Mol Sci. 21(24):9337. doi:10.3390/ijms21249337.
   Web of Science ®Google Scholar
• Cohen J. Some issue in power analysis. In: Cohen J, editor. Statistical power analysis for behavioral sciences. 2nd ed. Routlede; 2013. p. 531–42.
   Google Scholar
• Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, Yamada Y.New rat model induced by anti-glomerular basement membrane antibody shows severe glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol Int. 2008;58(6):361–70. doi:10.1111/j.1440-1827.2008.02237.x.
   PubMed Web of Science ®Google Scholar
• Sedláková L, Čertíková Chábová V, Doleželová Š, Škaroupková P, Kopkan L, Husková Z, Červenková L, Kikerlová S, Vaněčková I, Sadowski J, et al.Renin–angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. Clin Exp Hypertens. 2017;39(2):183–95. doi:10.1080/10641963.2016.1235184.
   PubMed Web of Science ®Google Scholar
• Hsu S, Bansal N.Updates in the management of heart failure for the chronic kidney disease patient. Curr Opin Nephrol Hypertens. 2019;28(3):262–66. doi:10.1097/MNH.0000000000000497.
   PubMed Web of Science ®Google Scholar
• Petersson M, Friberg P, Eisenhofer G, Lambert G, Rundqvist B.Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J. 2005;26(9):906–13. doi:10.1093/eurheartj/ehi184.
   PubMed Web of Science ®Google Scholar
• Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006;17(10):2886–91. doi:10.1681/ASN.2006010063.
   PubMed Web of Science ®Google Scholar
• Hillege HL, Girbes AR, De Kam PJ, Boomsma F, De Zeeuw D, Charlesworth A, Hampton JR, Van Veldhuisen DJ.Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102(2):203–10. doi:10.1161/01.CIR.102.2.203.
   PubMed Web of Science ®Google Scholar
• Patel KP, Zhang K, Carmines PK. Norepinephrine turnover in peripheral tissues of rats with heart failure. Am J Physiol. 2000;278:R556–R562.
   Google Scholar
• Lee MA, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mRen2)27. Am J Physiol. 1990;270:E919–E929.
   Google Scholar
• Kopkan L, Kramer HJ, Huskova Z, Vanourkova Z, Skaroupkova P, Thumova M, Cervenka L.The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens. 2005;23(8):1531–39. doi:10.1097/01.hjh.0000174972.46663.5e.
   PubMed Web of Science ®Google Scholar
• Melenovsky V, Skaroupkova P, Benes J, Torresova V, Kopkan L, Cervenka L.The course of heart failure development and mortality in rats with volume overload due to aorto-caval fistula. Kidney Blood Press Res. 2012;35(3):167–73. doi:10.1159/000331562.
   PubMed Web of Science ®Google Scholar
• Červenka L, Melenovský V, Husková Z, Sporková A, Burgelová M, Škaroupková P, Hwang SH, Hammock BD, Imig JD, Sadowski J. Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula. Physiol Res. 2015;64:857–73. doi:10.33549/physiolres.932977.
   PubMed Web of Science ®Google Scholar
• Kala P, Červenka L, Škaroupková P, Táborský M, Kompanowska-Jezierska E, Sadowski J. Sex-linked differences in the mortality in Ren-2 transgenic hypertensive rats with aorto-caval fistula: effects of treatment with angiotensin converting enzyme alone and combined with inhibitor of soluble epoxide hydrolase. Physiol Res. 2019;68:589–601. doi:10.33549/physiolres.934094.
   PubMed Web of Science ®Google Scholar
• Nishihara M, Takesue K, Hirooka Y.Olesartan combined with renal denervation reduces blood pressure in association with sympatho-inhibitory and aldosterone-reducing effects in hypertensive mice with chronic kidney disease. Clin Exp Hypertens. 2019;41(3):211–19. doi:10.1080/10641963.2018.1465075.
   PubMed Web of Science ®Google Scholar
• Han W, Wang M, Zhain X, Gan Q, Guan S, Qu X.Chemical renal denervation-induced upregulation of the ACE2/Ang (1-7)/Mas axis attenuates blood pressure elevation in spontaneously hypertensive rats. Clin Ex Hypertens. 2020;42(7):661–68. doi:10.1080/10641963.2020.1772812.
   PubMed Web of Science ®Google Scholar
• Bernard C. An introduction to the study of experimental medicine. New York: Dover Publications, Inc.; 2018.
   Google Scholar
• Riehle C, Bauersachs J.Small animal models of heart failure. Cardiovasc Res. 2019;115(13):1838–49. doi:10.1093/cvr/cvz161.
   PubMed Web of Science ®Google Scholar
• Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease. Adv Exp Med Biol. 2019;1165:487–500.
   PubMed Web of Science ®Google Scholar
• Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, Fisoufis K, Pocock S, Konstantinidis D, Choid JW, et al.Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicenter, randomized, sham-controlled trial. Lancet. 2020;395(10234):1444–51. doi:10.1016/S0140-6736(20)30554-7.
   PubMed Web of Science ®Google Scholar
• Lian Z, Yu S-R, Song J-X, Lee C-Y, Li S-F, Cui Y-X, Su L-N, Chen H.Efficacy and safety of catheter-based renal denervation for heart failure with reduced ejection fraction: a systematic review and meta-analysis. Clin Autonomic Res. 2020;30(6):521–30. doi:10.1007/s10286-020-00716-y.
   PubMed Web of Science ®Google Scholar
• Schmieder RE. Renal denervation: where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant 2020; Online ahead of print. doi:10.1093/ndt/gfaa237.
   PubMedGoogle Scholar